The headline trial: FLOW + SUSTAIN-6 + SELECT (triple-stacked evidence)
What the trial found:
- When all three conditions stack, semaglutide is the rare GLP-1 RA with positive outcomes in all three: FLOW HR 0.76 for kidney composite, SUSTAIN-6 HR 0.74 for MACE in T2D, SELECT HR 0.80 for MACE in obesity + CV.
- The combined indication footprint makes semaglutide the dominant choice when this trifecta presents.
Full trial detail
FLOW (Perkovic NEJM 2024) for kidney protection; SUSTAIN-6 (Marso NEJM 2016) for T2D + CV outcomes; SELECT (Lincoff NEJM 2023) for obesity + CV outcomes without T2D
Three NEJM publications 2016 to 2024
When all three conditions stack, semaglutide is the rare GLP-1 RA with positive outcomes in all three: FLOW HR 0.76 for kidney composite, SUSTAIN-6 HR 0.74 for MACE in T2D, SELECT HR 0.80 for MACE in obesity + CV. The combined indication footprint makes semaglutide the dominant choice when this trifecta presents.
Trial enrollment criteria
- T2D documented with ICD-10 E11.x
- CKD stage 3 or 4 (eGFR 25 to 75) with albuminuria documented
- Established CV disease: prior MI, stroke, TIA or symptomatic PAD
- On maximum tolerated ACE inhibitor or ARB and statin therapy
Does this trial apply to you?
This is the highest-defensibility PA case in the GLP-1 universe. Three FDA-labeled indications stack onto a single drug. Most prescribers will file under the T2D indication (E11.x) with CKD and CV history documented as supporting context; the PA letter will be approved on the first pass at any reasonable plan. Care coordination across nephrology, cardiology and endocrinology is essential.
What to ask your prescriber
- Whether all three indications are documented in your chart with ICD-10 codes
- Most recent eGFR, UACR, A1c, lipid panel and cardiac imaging
- Whether semaglutide 1.0 mg (FLOW dose) or 2.4 mg (SELECT dose) is appropriate for your dominant clinical concern
- Coordination between PCP, cardiologist and nephrologist on the prescribing pathway
Editorial notes
- Triple-indication patients are the most under-treated GLP-1 population in the US per AHA/ACC/ADA 2025 guidelines.
- Hypoglycemia risk is real when adding semaglutide to insulin or sulfonylurea; deintensify those agents proactively.
- Blood pressure may drop substantially in the first 8 weeks; coordinate dose adjustments with cardiology.
Or see the best programs for T2D + CKD + ASCVD, ranked and reviewed.
Clinical trials for Type 2 diabetes with chronic kidney disease and established cardiovascular disease
Or browse the full GLP-1 clinical trials directory, filterable by condition, state and phase.
Take it to your prescriber: PA letter templates
Editable prior-authorization letter templates that cite the registration trial above. Pick the plan your prescriber will submit to, copy the template, fill in the patient-specific findings and have your clinician sign and submit.
type 2 diabetes
Commercial and Medicare Advantage plans
CV risk (Wegovy)
Commercial and Medicare Advantage plans
Not seeing your plan? The full PA letter library covers 20 plans × 10 indications = 200 templates. The appeal letter library handles denials.
Drug profiles
Other GLP-1 conditions
Editorial provenance
Editorial review by John, Editor on 2026-05-23, against FLOW + SUSTAIN-6 + SELECT (triple-stacked evidence) (Three NEJM publications 2016 to 2024). We do not yet have a credentialed medical reviewer on staff (actively recruiting). This page summarises public registration-trial data and FDA labeling. It is not clinician-authored medical advice.
Disclaimer
Educational summary of published registration trial data. Not medical advice. Not a substitute for evaluation by a treating clinician. Trial-level results do not guarantee individual outcomes. Discuss eligibility, contraindications, dose adjustments and drug interactions with your prescriber. We do not have a credentialed medical reviewer on staff yet (actively recruiting); the content below is editor-written from public registration-trial publications and FDA labeling, not clinician-authored medical advice.